“…Specifically, ASTX has been shown to inhibit the migration, invasion, and/or proliferation of cancerous gastric [ 36 ], liver [ 37 ], ovarian [ 38 ], breast [ 39 ], colon [ 40 ], and melanoma cells [ 41 ]. In addition, ASTX is known to target cancer-related signal transduction pathway proteins and their regulators, namely inflammatory cytokines, membrane receptors (e.g., peroxisome proliferator-activated receptor gamma (PPARγ), transcriptional regulators (e.g., NF-κB, signal transducer and activator of transcription 3 (STAT3), NF-2-related factor 2 (Nf2), and zinc finger E-box binding homeobox (ZEB)), and protein kinases (e.g., janus kinase (JAK), protein kinase B (PKB), phosphoinositide 3-kinase (PI3K) and the MAP kinases c-Jun N -terminal kinase (JNK), extracellular signal-related kinase (ERK), and p38) [ 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ].…”